Blood-borne cancer cells--quo vadis?

Int J Biol Markers. 2000 Jan-Mar;15(1):111-3. doi: 10.1177/172460080001500121.

Abstract

The detection of blood-borne cancer cells may help in clinical staging and further understanding of cancer metastasis. We developed a cytokeratin-based immunomagnetic method to isolate epithelium-derived cells from the circulating blood of patients. The number of cell clusters positive for cytokeratin/prostate-specific antigen (PSA) from the peripheral blood of prostate cancer patients and cytokeratin/p185c-erbB-2 from the peripheral blood of breast cancer patients has been related to stage of the disease. Breast cancer patients who presented cytokeratin/p185c-erbB-2-positive cell clusters showed a decrease in such cells under adriamycin adjuvant therapy with Further molecular characterization by a highly sensitive microsatellite multiplex-PCR enabled reproducible detection of microsatellite alterations. The impact of these individually targeted results may contribute to an individual diagnostic and therapeutic strategy.

MeSH terms

  • Biomarkers / blood
  • Epithelial Cells / cytology
  • Epithelial Cells / pathology
  • Humans
  • Keratins / analysis
  • Keratins / blood
  • Neoplasm Metastasis
  • Neoplasm Staging
  • Neoplasms / blood*
  • Neoplasms / pathology*

Substances

  • Biomarkers
  • Keratins